EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?

Philipp Mahlknecht, Werner Poewe

Journal of Parkinson’s Disease · 2024

DOI: 10.3233/jpd-230354 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, 2024. Verfasst von Philipp Mahlknecht und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Slowing or halting progression continues to be a major unmet medical need in Parkinson’s disease (PD). Numerous trials over the past decades have tested a broad range of interventions without ultimate success. There are many potential reasons for this failure and much debate has focused on the need to test ‘disease-modifying’ candidate drugs in the earliest stages of disease. While generally accepted as a rational approach, it is also associated with significant challenges around the selection of trial populations as well as trial outcomes and durations. From a health care perspective, intervening even earlier and before at-risk subjects have gone on to develop overt clinical disease is at the heart of preventive medicine. Recent attempts to develop a framework for a biological definition of PD are aiming to enable ‘preclinical’ and subtype-specific diagnostic approaches. The present review addresses past efforts towards disease-modification, including drug targets and reasons for failure, as well as novel targets that are currently being explored in disease-modification trials in early established PD. The new biological definitions of PD may offer new opportunities to intervene even earlier. We critically discuss the potential and challenges around planning ‘disease-prevention’ trials in subjects with biologically defined ‘preclinical’ or prodromal PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansAntiparkinson AgentsDisease ProgressionEarly Medical Intervention

Stichwörter der Autor:innen

Parkinson’s disease (PD)biological definition of PDdisease-modificationdisease-preventionneuroprotectionpreclinical PDprodromal PD

Substanzen

Antiparkinson Agents

Autor:innen und Institutionen

  • Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

Zitieren

APA

Mahlknecht, P., & Poewe, W. (2024). Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-230354

Vancouver

Mahlknecht P, Poewe W. Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?. Journal of Parkinson’s Disease. 2024. doi:10.3233/jpd-230354

BibTeX
@article{Mahlknecht2024,
  author = {Mahlknecht, Philipp and Poewe, Werner},
  title = {Pharmacotherapy for Disease Modification in Early Parkinson’s Disease: How Early Should We Be?},
  journal = {Journal of Parkinson’s Disease},
  year = {2024},
  doi = {10.3233/jpd-230354}
}
Kostenlos starten →